Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates

American Journal of Gastroenterology

Volumn 104, Issue 9, 2009, Pages 2222-2232

  Rubenstein, Joel H ^a,b   Waljee, Akbar K ^a   Jeter, Joanne M ^c   Velayos, Fernando S ^d   Ladabaum, Uri ^d   Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; CANCER INCIDENCE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MESALAMINE; MIDDLE AGED;

EID: 69949112656     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.264     Document Type: Article

References (62)

1. Eaden JA, Abrams KR, Mayberry JF. Th e risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
2. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003; 124: 544-60.
3. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85.
4. Anonymous. Th e role of colonoscopy in the management of patients with infl ammatory bowel disease. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1998; 48: 689-90.
5. Steven HI, Noam H. Diagnosis and management of dysplasia in patients with infl ammatory bowel diseases. Gastroenterology 2004; 126: 1634-48.
6. van Staa TP, Card T, Logan RF et al. 5-Aminosalicylate use and colorectal cancer risk in infl ammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-8.
7. Eaden J, Abrams K, Ekbom A et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Th er 2000; 14: 145-53.
8. Pinczowski D, Ekbom A, Baron J et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117-20.
9. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. Th e impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44: 77-85.
10. Terdiman JP, Steinbuch M, Blumentals WA et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with infl ammatory bowel disease. Infl amm Bowel Dis 2007; 13: 367-71.
11. Bernstein CN, Blanchard JF, Metge C et al. Does the use of 5-aminosalicylates in infl ammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003; 98: 2784-8.
12. Velayos FS, Terdiman JP, Walsh JM. Eff ect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53.
13. Stolfi C, Fina D, Caruso R et al. Cyclooxygenase-2-dependent and-independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 2008; 75: 668-76.
14. Fang HM, Mei Q, Xu JM et al. 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol 2007; 13: 2872-7.
15. Chu EC, Chai J, Ahluwalia A et al. Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Th er 2007; 25: 1443-9.
16. Luciani MG, Campregher C, Fortune JM et al. 5-ASA aff ects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007; 132: 221-35.
17. Fina D, Franchi L, Caruso R et al. 5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. Eur J Cancer 2006; 42: 2609-16.
18. Monteleone G, Franchi L, Fina D et al. Silencing of SH-PTP2 defi nes a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Diff er 2006; 13: 202-11.
19. Brown WA, Farmer KC, Skinner SA et al. 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 2000; 45: 1578-84.
20. Reinacher-Schick A, Schoeneck A, Graeven U et al. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003; 24: 443-51.
21. Bus PJ, Nagtegaal ID, Verspaget HW et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Th er 1999; 13: 1397-402.
22. Reinacher-Schick A, Seidensticker F, Petrasch S et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000; 32: 245-54.
23. Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis. Gut 2000; 46: 500-6.
24. Provenzale D, Wong JB, Onken JE et al. Performing a cost-eff ectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 1998; 93: 872-80.
25. Provenzale D, Kowdley KV, Arora S et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995; 109: 1188-96.
26. Schrag D. Th e price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-9.
27. SEER Cancer Statistics Review, 1975-2002. In Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Mariotto A, Feuer E, Edwards B (eds). National Cancer Institute: Bethesda, MD, Accessed: November 2, 2007: based on November 2004 SEER data submission, posted to the SEER web site 2005.
28. Card T, Hubbard R, Logan RF. Mortality in infl ammatory bowel disease: a population-based cohort study. Gastroenterology 2003; 125: 1583-90.
29. Winther KV, Jess T, Langholz E et al. Survival and cause-specifi c mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003; 125: 1576-82.
30. Choi PM, Nugent FW, Schoetz DJ Jr et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-24.
31. Ullman T, Croog V, Harpaz N et al. Progression to colorectal neoplasia in ulcerative colitis: eff ect of mesalamine. Clin Gastroenterol Hepatol 2008; 6: 1225-30; quiz 1177.
32. Bax L, Yu L, Ikeda N et al. Development and validation of MIX: comprehensive free soft ware for meta-analysis of causal research data. BMC Med Res Methodol 2006; 6: 50.
33. Bax L, Yu L, Ikeda N et al. MIX: Comprehensive free soft ware for metaanalysis of causal research data - version 1.7. http://www.mix-for- metaanalysis. info, 2008.
34. Gold MR, Siegel JE, Russell LB.: et al. Cost-Eff ectiveness in Health and Medicine. Oxford University Press: New York, 1996.
35. Gossner L, May A, Stolte M et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointestinal Endoscopy 1999; 49: 8-12.
36. Yen E, Kane S, Ladabaum U. Cost-eff ectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. American Journal of Gastroenterology 2008; 103: 3094-105.
37. Higgins PDR, Schwartz M, Mapili J et al. Patient defi ned dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-8.
38. Ubel PA, Hirth RA, Chernew ME et al. What is the price of life and why doesn' t it increase at the rate of infl ation? Archives of Internal Medicine 2003; 163: 1637-41.
39. Spiegel BM, Ho W, Esrailian E et al. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clinical Gastroenterology & Hepatology 2009; 7: 168-74.
40. Lashner BA, Provencher KS, Seidner DL et al. Th e eff ect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32.
41. Pardi DS, Loft us EV Jr, Kremers WK et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.[see comment]. Gastroenterology 2003; 124: 889-93.
42. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in infl ammatory bowel disease. American Journal of Gastroenterology 1996; 91: 44-8.
43. Velayos FS, Loft us EV Jr, Jess T et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 1941-9.
44. Poynter JN, Gruber SB, Higgins PDR et al. Statins and the risk of colorectal cancer. New England Journal of Medicine 2005; 352: 2184-92.
45. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of infl ammatory bowel disease. Gastroenterology Clinics of North America 2006; 35: 675-712.
46. Langholz E, Munkholm P, Davidsen M et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
47. Winther KV, Jess T, Langholz E et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clinical Gastroenterology & Hepatology 2004; 2: 1088-95.
48. Lashner BA, Hanauer SB, Silverstein MD. Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med 1988; 108: 274-8.
49. Rubin CE, Haggitt RC, Burmer GC et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103: 1611-20.
50. Frykholm G, Pahlman L, Enblad P et al. Early outcome aft er emergency and elective surgery for ulcerative colitis. Acta Chir Scand 1989; 155: 601-5.
51. Longo WE, Virgo KS, Johnson FE et al. Risk factors for morbidity and mortality aft er colectomy for colon cancer. Dis Colon Rectum 2000; 43: 83-91.
52. Dominitz JA, Eisen GM, Baron TH et al. Complications of colonoscopy. Gastrointest Endosc 2003; 57: 441-5.
53. Garbay JR, Suc B, Rotman N et al. Multicentre study of surgical complications of colonoscopy. Br J Surg 1996; 83: 42-4.
54. Murray L. 2004 Red Book, 108 edn. Th omson PDR: Montvale, NJ, 2004.
55. Hay AR, Hay JW. Infl ammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14: 318-27.
56. Ikeuchi H, Nakano H, Uchino M et al. Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients. Digestive Surgery 2004; 21: 197-201.
57. Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. Journal of the Royal College of Surgeons of Edinburgh 2001; 46: 334-7.
58. Shen B, Shermock KM, Fazio VW et al. A cost-eff ectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis. American Journal of Gastroenterology 2003; 98: 2460-7.
59. Berkowitz N, Gupta S, Silberman G. Medical resource utilization and cost in patients following colectomy. Managed Care and Cancer 2000; 2: 14-21.
60. Pyenson B, Connor S, Fitch K et al. Medicare cost in matched hospice and non-hospice cohorts. J Pain Symptom Manage 2004; 28: 200-10.
61. Muir AJ, Edwards LJ, Sanders LL et al. A prospective evaluation of healthrelated quality of life aft er ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001; 96: 1480-5.
62. Ness RM, Holmes AM, Klein R et al. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999; 94: 1650-7.